Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1985 Nov;50(2):495-9.
doi: 10.1128/iai.50.2.495-499.1985.

Role of lipopolysaccharide and complement in susceptibility of Haemophilus ducreyi to human serum

Role of lipopolysaccharide and complement in susceptibility of Haemophilus ducreyi to human serum

J A Odumeru et al. Infect Immun. 1985 Nov.

Abstract

The role of lipopolysaccharide (LPS) in the susceptibility of Haemophilus ducreyi to human serum and the mechanism of complement activation by serum-susceptible (Sers) strains were investigated. Serum treated with 2 mM Mg2+ and 20 mM ethylene glycol-bis(beta-aminoethyl ether)-N,N,N',N'-tetraacetic acid was nonbactericidal, but inulin-treated serum remained bactericidal. Absorption of serum with heat-killed whole cells of an Sers strain removed its bactericidal activity against the absorbing strain and also against other Sers strains. LPS obtained from Sers strains inhibited the bactericidal activity of serum against all Sers strains, whereas LPS from serum-resistant (Serr) strains and an Serr isogenic strain did not. However, high concentrations of LPS from the Serr strain inhibited the bactericidal activity of serum, an indication that part of the structural site involved in serum susceptibility is retained in the LPS of this strain. The LPS of Sers strains exhibited higher anticomplement activity than the LPS of Serr strains. These findings suggest that the classical pathway of complement activation is involved in the serum killing of H. ducreyi and that LPS composition may contribute to their susceptibility to complement-mediated serum bactericidal activity.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Infect Immun. 1982 Jan;35(1):95-104 - PubMed
    1. Infect Immun. 1982 Mar;35(3):759-63 - PubMed
    1. Infect Immun. 1978 Feb;19(2):515-22 - PubMed
    1. J Immunol. 1972 Oct;109(4):807-9 - PubMed
    1. Infect Immun. 1980 May;28(2):359-67 - PubMed

Publication types

Substances

LinkOut - more resources